Market Size (2016)
2016
$884.70M
Vertical: HealthcareBase Year: 201812 Sections
Market Size (2016)
2016
$884.70M
Projected (2025)
2025
$1.64B
CAGR (2016–2025)
7.1%
7.1%Key Players
104+
Glioblastoma is a type of brain tumor. The cells in glioblastoma resemble astrocyte cells that normally nurture and provide sustenance to the neurons as well as respond to the injury of the brain tissue. A stem cell or immature astrocyte is the cell of origin that attains a genetic abnormality and ultimately grows into an entire population of cancerous glioblastoma cells. This can spread quickly throughout the brain, overrunning normal brain cells.
The Glioblastoma Market market is projected to grow at a CAGR of 7.1% from 2016 to 2025.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansGlioblastoma is a tumor that forms from star-shaped cells in the brain called astrocytes. The increasing occurrences of glioblastoma coupled with increasing research activities in glioblastoma treatment and rising adoption of chemotherapy are expected to fuel the growth of the global glioblastoma market
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansBargaining Power of Suppliers
Currently, the market consists of several players manufacturing novel drugs as well as generic drug producers. However, few existing key companies capture significant share in the market and have the capability of fluctuating the costs of the products. Another factor affecting the bargaining power of suppliers is the switching cost for buyers. Since there are a lot of generic drugs for the treatment of glioblastoma, this gives a moderate level of leverage to the buyers to switch. Furthermore, many companies are focusing on the development of new treatment options, which increases competition in the market. Therefore, the overall bargaining power of suppliers in the global glioblastoma market is moderate.
Bargaining Power of Buyers
The bargaining power of buyers is low to moderate in the global glioblastoma market. Patients are the primary buyers in the market through different distribution channels such as hospitals and retail pharmacies. The presence of buyers in the market is rising due to the increasing prevalence of glioblastoma and brain tumors. Also, some buyers are price-sensitive, which moderately affects their bargaining power in the market. The market is characterized by moderate availabilities of substitute products, which reduces the buying power to an extent.
Threat of New Entrants
The threat of new entrants is moderate in the global glioblastoma market due to the development of the potential market. Any company trying to enter the market has to get the product approved and certified by various regulatory authorities in different countries. The rising awareness regarding glioblastoma and its severity among the patients pushes the currently established and other manufacturers to focus more on its treatment alternatives. There is a stronghold of the big companies in this market, which can make the entry of the new players a bit difficult. Moreover, many key companies in the market have failed clinical trials after reaching phase III. This negatively affects the decision of medium-sized companies to enter into this market as they do not have much capital to invest in the field.
Threat of Substitutes
The threat of substitutes in the global glioblastoma market is moderate. The substitutes in the market constitute the generic versions of drugs available in the market. Although there are a moderate number of substitutes available in the market, the buyer’s propensity to substitute is low as most of the medical professionals prescribe a limited number of drugs for the treatment of glioblastoma. Additionally, quality, trust issues, and excellent service provided by the existing established players restrict the threat by the substitutes.
Intensity of Rivalry
The degree of competition in the global glioblastoma market is moderate to high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Companies involved in the global glioblastoma market are trying to develop cost-effective products to make product differentiation more affordable. To overcome the competition, players are engaged in developing a process to lower their manufacturing cost. Moreover, the players are also developing advanced techniques for differentiating their product from their rivals.
Market estimates by geography (2025)
InsightNorth America leads with $637.00M by 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $37.10M | $51.10M | $63.00M | 6.1% | 4% |
| North America | $332.90M | $467.10M | $637.00M | 7.5% | 39% |
| Asia Pacific | $173.40M | $232.90M | $317.90M | 7.0% | 19% |
| Europe | $297.70M | $414.30M | $543.30M | 6.9% | 33% |
| South America | $43.70M | $61.70M | $82.20M | 7.3% | 5% |
| Total | $884.80M | $1.23B | $1.64B | 7.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$854.56M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Primary Glioblastoma | $765.77M | 7.1% | 85% |
| Secondary Glioblastoma | $88.79M | 7.1% | 40% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Glioblastoma Market covering market dynamics, competitive landscape, and strategic outlook.
The Glioblastoma Market market is projected to reach $1.64B by 2025, growing at 7.1% CAGR. The Primary Glioblastoma segment holds the largest share.
Glioblastoma are malignant grade IV tumors. Glioblastoma are infiltrative and can invade into nearby areas of the brain. These tumors predominantly constitute abnormal astrocytic cells, but also may contain different types of blood vessels and dead cells. Factors such as increasing incidence rates of glioblastoma, growing research on glioblastoma and brain tumors, and rising adoption of chemotherapy are expected to fuel the growth of the global glioblastoma market. However, the high cost of drugs and the failure of drug candidates in clinical trial phases are anticipated to hamper the market growth. On the other hand, upcoming treatment alternatives are expected to be a strong opportunity for the market.
The increasing incidence rate of glioblastomas is expected to fuel the growth of the global glioblastomas market. According to the statistics published in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastomas has an incidence rate of 3.19 per 100,000 persons in the US. Also, according to the statistics updated by American Brain Tumor Association in 2018, glioblastomas represents about 15% of all primary brain tumors.
Similarly, the American Association of Neurological Surgeons suggests that glioblastomas account for approximately 17% of the brain tumors (primary and metastatic). The increasing incidence rate indirectly increases the healthcare spending of the people as well as the government. This pushes the players operating in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma over the forecast period.
Since glioblastomas is recurrent, there is rigorous research going on in his field to search for new tools for the treatment of this type of tumor. Various researchers are trying to incorporate different approaches such as gene therapies and innovative immunotherapies for the better treatment of glioblastoma. One of them is the integration of proton therapy. Proton therapy is an advanced technology to deliver radiation treatment to cancerous tumors. Proton therapy has fewer side-effects as it delivers less radiation to healthy organs and tissues. In pediatric cancers, proton therapy has huge benefits such as good rate of curability, fewer side-effects than the standard radiation therapy, and reduction in the risk of development of secondary cancer. As it is painless and non-invasive, most patients retain a high quality of life at the time and after treatments. All these benefits provide a global recognition of proton therapy in the treatment of brain tumors. Scientists are currently working on it as this therapy can be used in conjunction with surgery or chemotherapy. Thus, this can create lucrative options for top companies in the future.
The Brain Tumor Charity suggests that only 3.3% of the patients suffering from glioblastoma survive beyond two years and that glioblastoma is extremely difficult to treat as it spreads to other parts of the brain in a short period. A lot of major companies who have invested in the research and development of glioblastoma drugs are suffering from setbacks. For instance, in May 2019, Bristol Myers Squibb announced that its drug candidate CheckMate -498 did not meet the set primary endpoint. Similarly, in May 2016, Actelion announced the termination of a clinical study on the safety and tolerability of Macitentan in combination with dose-dense temozolomide in patients with recurrent glioblastoma. This elucidates a confusion for medium-sized players to enter the market, thus restraining the growth of the market. Also, the company who has a failed clinical trial history might be unsure about continuing in the market. All these factors are resulting in the monetary loss for these companies, thus hindering the growth of the market over the assessment period.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the Glioblastoma Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Amgen Inc.
Company Overview Company Headquarters: California, US Founded: 1980 Workforce: 20,000+ Company Working: Amgen Inc. (Amgen), a well-known biopharmaceutical company, was founded in 1860. The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutic products. It uses tools such as advanced human genetics to unravel the intricacies of diseases and understand the fundamentals of human biology. It serves its products in major therapeutic areas such as oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen operates through one business segment, namely, human therapeutics. It focuses on areas that have high unmet medical needs and leverages its expertise to develop solutions for improving health outcomes and efficiently improve people's lives. It has become one of the leading independent biotechnology companies in the world.
Teva Pharmaceutical Industries Ltd
Company Headquarters: Petah Tikva, Israel Founded: 1901 Workforce: 43,000+ Company Working: Teva Pharmaceutical Industries Ltd (Teva) is one of the leaders in pharmaceutical industries engaged in developing and providing services in generic medicines. The company has more than 1,800 molecules which are used to create an extensive variety of generic products in almost every therapeutic area. It is specialized in generic medicines, the central nervous system (CNS), brand and specialty medicines, oncology, active pharmaceutical ingredients, respiratory, women's health, and biologics fields. It has more than 35,000 unique products, which is more than any other pharmaceutical company. Teva produced 120 billion tablets and capsules in 2017. Geographically, it operates in regions, namely, North America, Latin America, Europe, Japan, and South Korea. The company operates in more than 60 countries worldwide. It has 26 FDA approved plants, and 31 European Medicines Agency (EMA) approved plants worldwide.
F. HOFFMANN-LA ROCHE LTD
Incorporated in 1896 and headquarters in Basel, Switzerland; F. Hoffmann-La Roche AG is the world's biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is additionally the world pioneer in vitro diagnostics and tissue-based cancer diagnostics, and a leader in diabetes management. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The products offered by the company helps in tapping in the world’s two third of all the diseases which are either not treated effectively or not treated at all. The company offers various products in the Pharmaceutical, Diagnostics and research industry. Geographically the company operates in North America, Europe, South America, Africa, Asia and Oceania. As of 2015 F. Hoffmann-La Roche AG had a head count of 91,700 + employees world wide Roche Strategy – a methodology that intends to fit the right treatment to every patient in the most ideal way that could be available dedicated on developing innovative diagnostic tests and medicines which will help their patients and the world.
Sun Pharmaceutical Industries Ltd
Company Headquarters: Mumbai, India Founded: 1983 Workforce: ~30,000 Company Working: Sun Pharmaceutical Industries Ltd (Sun Pharma) is one of India’s top pharmaceutical companies. It is the world’s fourth-largest generic pharmaceutical company. The company has vertically integrated businesses, high economies of scale, and a highly-skilled team. Sun Pharma delivers high-quality and reasonable medicines trusted by customers in over 150 countries globally, such as the US, Canada, Brazil, Germany, France, Russia, Japan, and South Africa. It also has a specialty products portfolio which contains ten specialty products, out of which five are in the market, three are likely to be commercialized soon, and two are awaiting USFDA approvals. It has its products in various leading therapeutic areas such as diabetes, oncology, pain, autoimmune diseases, respiratory diseases, antibiotics and vaccines, cardiovascular, HIV, mental health, and antivirals. Sun Pharma sells its duloxetine and atorvastatin products under the brand name AZTOR.
Novavax, Inc.
Company Headquarters: Maryland, US Founded: 1987 Workforce: ~2,500 Company Working: Novavax, Inc. is a biotechnology company that commercializes and develops vaccines to prevent a wide range of infectious diseases. It designs recombinant nanoparticle vaccine technology that produces a strong immune response against a variety of pathogens. It is partnered with leading biopharma organizations, government agencies, research institutions, and foundations, namely the Coalition for Epidemic Preparedness Innovations (US), the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (US), the Serum Institute of India Pvt. Ltd. (India), SK Bioscience (South Korea), CPL Biological (India), and Takeda Pharmaceuticals (US). It has seven research and manufacturing facilities. It has presence in regions namely North America, Europe, and the Middle East and Africa
Ology Bioservices, Inc
Company Headquarters: Florida, US Founded: 1999 Workforce: ~800 Company Working: Ology Bioservices, Inc. is an integrated biopharmaceutical company that develops and manufactures biopharmaceuticals and medical devices. It specializes in cell therapy, gene therapy, viral vectors, antibodies, oncolytic viruses, biopharmaceutical manufacturing, and vaccines. It has collaboration and partnerships with recognized government agencies, namely the Department of Defense and Medical Countermeasures Advanced Development and Manufacturing, which support it in developing biodefense products. Moreover, it has decades of experience in developing, licensing, and manufacturing proteins, therapeutics, and vaccines. It develops products to offer both commercial customers and US governments. Furthermore, it is a wholly owned company of National Resilience, Inc. (US), and assisting Resilience through its services includes regulatory support from preclinical through licensure and cGMP manufacturing up to biosafety level 3 (BSL3).
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Glioblastoma Market